All In Biotech

Drug Trial Radar · NCT07063745

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 590 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

590

Planned (sponsor's estimate)

Start

Jan 2, 2026

Primary completion

Aug 12, 2031

Study completion Aug 12, 2031

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Conditions

  • Metastatic Non-small Cell Lung Cancer With MTAP Deletion

Interventions

  • BMS-986504Drug

    Specified dose on specified days

  • PembrolizumabDrug

    Specified dose on specified days

  • PlaceboOther

    Specified dose on specified days

  • CisplatinDrug

    Specified dose on specified days

  • CarboplatinDrug

    Specified dose on specified days

  • PemetrexedDrug

    Specified dose on specified days

  • PaclitaxelDrug

    Specified dose on specified days

  • Nab-paclitaxelDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) by RECIST v1.1Time frame: Up to 2 years
  2. PFS by RECIST v1.1 per BICRTime frame: Up to 5 years
  3. Overall Survival (OS)Time frame: Up to 5 years

Locations

321 sites in 34 countries. Site status is shown where the registry gives one.

  • Local Institution - 0119

    Anchorage, Alaska · Completed

  • Mayo Clinic in Arizona - Phoenix

    Phoenix, Arizona · Recruiting

  • University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • Local Institution - 0497

    Los Alamitos, California · Not yet recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Local Institution - 0444

    Los Angeles, California · Withdrawn

  • Local Institution - 0606

    Newark, Delaware · Withdrawn

  • Helios Clinical Research - Fort Lauderdale

    Fort Lauderdale, Florida · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • Local Institution - 0430

    St. Petersburg, Florida · Withdrawn

  • Local Institution - 0523

    Tampa, Florida · Not yet recruiting

  • St. Luke's Cancer Institute: Boise

    Boise, Idaho · Recruiting

  • Cancer Care Specialists of Illinois - Cancer Care Center of O'Fallon

    Decatur, Illinois · Recruiting

  • Baptist Health Lexington

    Lexington, Kentucky · Recruiting

  • University of Kentucky Chandler Medical Center

    Lexington, Kentucky · Recruiting

  • Local Institution - 0127

    Scarborough, Maine · Not yet recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Local Institution - 0418

    Ann Arbor, Michigan · Not yet recruiting

  • Local Institution - 0405

    Detroit, Michigan · Not yet recruiting

  • Local Institution - 0420

    Traverse City, Michigan · Not yet recruiting

  • Mayo Clinic in Rochester, Minnesota

    Rochester, Minnesota · Recruiting

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Local Institution - 0467

    Lebanon, New Hampshire · Not yet recruiting

  • Local Institution - 0600

    Manchester, New Hampshire · Not yet recruiting

  • WMCHealth Advanced Physician Services

    Hawthorne, New York · Recruiting

  • Local Institution - 0128

    Rochester, New York · Not yet recruiting

  • Ellis Hospital

    Schenectady, New York · Recruiting

  • Local Institution - 0514

    Winston-Salem, North Carolina · Not yet recruiting

  • Local Institution - 0163

    Cleveland, Ohio · Withdrawn

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Providence Portland Medical Center

    Portland, Oregon · Recruiting

  • Kaiser Permanente Interstate Medical Office Central

    Portland, Oregon · Recruiting

  • Local Institution - 0559

    Hershey, Pennsylvania · Withdrawn

  • Local Institution - 0608

    Greenville, South Carolina · Not yet recruiting

  • Local Institution - 0515

    Knoxville, Tennessee · Withdrawn

  • UT Southwestern Medical Center Simmons Comprehensive Cancer Center

    Dallas, Texas · Recruiting

  • Local Institution - 0374

    El Paso, Texas · Completed

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Local Institution - 0377

    The Woodlands, Texas · Withdrawn

Showing 40 of 321 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.